Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie has recently completed a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aimed to assess changes in disease activity, adverse events, and drug pharmacokinetics in adults with HIV. This research is significant as it explores potential new treatments for a chronic condition requiring lifelong therapy.
The study tested two investigational drugs, Budigalimab and ABBV-382, administered either intravenously or subcutaneously. These drugs are intended to treat HIV by evaluating their efficacy and safety in combination with stable antiretroviral therapy.
The study was designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model and quadruple masking. Its primary purpose was to evaluate treatment efficacy, involving 160 participants across 90 global sites.
The study began on September 5, 2023, with a primary completion date in 2025. The last update was submitted on September 29, 2025. These dates are crucial as they mark the progression and current status of the study.
The completion of this study could influence AbbVie’s stock performance positively, as successful results may enhance investor confidence and market position. In the competitive landscape of HIV treatment, advancements from this study could position AbbVie favorably against its peers.
The study is now completed, with further details available on the ClinicalTrials portal.